<DOC>
	<DOCNO>NCT02309580</DOCNO>
	<brief_summary>This Phase 1 clinical trial , type research study . The purpose phase 1 clinical trial find whether new study drug , ibrutinib , safe patient T-cell non-Hodgkin lymphoma either come back responded treatment . In phase 1 study , different dos ibrutinib ( 560 mg 840 mg daily ) test see effect drug patient disease .</brief_summary>
	<brief_title>Study Ibrutinib Relapsed Refractory T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<criteria>Pathology confirm relapsed refractory Tcell lymphoma ( PTCL stage &gt; IBCTCL ) treat institution Relapse progression least 1 systemic therapy Age ≥18 year time signing informed consent form Able adhere study visit schedule protocol requirement Previous systemic anticancer therapy must discontinue least 3 week prior treatment study . If progression disease therapy adverse effect resolve Grade 1 baseline , case 2 week acceptable Previous radiation , hormonal therapy , surgery must discontinue least 2 week prior treatment study adverse effect must resolve . Lymph node diagnostic biopsy within 2 week consider exclusionary Systemic corticosteroid permissible follow circumstance : Short course systemic corticosteroid disease control , improvement performance status noncancer indication ( ≤ 7 day ) must discontinue least 7 day prior study treatment . Ongoing administration stable dose corticosteroid therapy ( previously receive ≥ 30 day ) permissible provide evidence measurable disease increase steroid dose clinical trial ECOG performance status ≤ 2 study entry Patients undergone autologous stem cell transplant &gt; 6 month prior eligible Patients undergone allogeneic stem cell transplant &gt; 12 month , without active graftversushostdisease , immunosuppression prevention graftversushost disease eligible Laboratory test result within range : Adequate hematologic function screen laboratory assessment define : Absolute neutrophil count &gt; 1,000 cells/mm3 ( 1.0 x 10^9/L ) Platelet count &gt; 75,000 cells/mm3 ( 75 x 10^9/L ) , thrombocytopenia due bone marrow involvement platelet count must ≥ 50,000 cells/mm3 Hemoglobin &gt; 8.0 g/dL Adequate hepatic renal function screen laboratory assessment define : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 x upper limit normal ( ULN ) Creatinine &lt; 2.0 x ULN Estimated Glomerular Filtration Rate GFR [ CockcroftGault ] &gt; 30 mL/min . Bilirubin &lt; 1.5 x ULN [ unless bilirubin rise due Gilbert 's syndrome ( define &gt; 80 % unconjugated hyperbilirubinemia ) nonhepatic origin ] Females childbearing potential ( FCBP ) † must negative serum pregnancy test agree use appropriate method birth control Patients standard curative option lymphoid malignancy current state disease exclude . For eligibility trial , allogeneic stem cell transplantation consider standard curative option Concurrent systemic immunosuppressant therapy ( eg , cyclosporine A , tacrolimus , etc . ) within 28 day first dose study drug Recent infection require intravenous antiinfective treatment complete ≤14 day first dose study drug Known bleeding diathesis ( eg , von Willebrand 's disease ) hemophilia Treatment warfarin Vitamin K antagonist ( eg , phenprocoumon ) Any lifethreatening illness , medical condition , organ system dysfunction , opinion investigator , could compromise subject 's safety put study outcome undue risk Unwilling unable participate require study evaluation procedure . Unable understand purpose risk study provide sign date informed consent form ( ICF ) Currently active , clinically significant cardiovascular disease , uncontrolled arrhythmia class 3 4 congestive heart failure define New York Heart Association Functional Classification ; history myocardial infarction , unstable angina , acute coronary syndrome within 6 month prior enrollment Unable swallow capsule , malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease ulcerative colitis , partial complete bowel obstruction Pregnant female ( Lactating female must agree breast feed take ibrutinib Prior use ibrutinib Known seropositive require antiviral therapy human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) define PCR . Active concurrent malignancy require active therapy Known central nervous system meningeal involvement ( absence symptom investigation central nervous system involvement require ) Patients require treatment strong cytochrome P450 ( CYP ) 3A inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ibrutinib</keyword>
	<keyword>14-227</keyword>
</DOC>